Loading....
Stock Quote
ACCP (OTCBB)Last Trade
Change
Open
Bid
Ask
Volume2.00
0.00
N/A
1.90
2.00
0*quotes delayed at least 15 minutesContacts
- 2600 Stemmons Freeway,
- Suite 176
- Dallas, TX 75207-2107
- Tel: (214) 905-5100
Sign Up For News Alerts
Management Team
On the Web
Latest Tweets
Follow Us
Accesspharma: RT @Gastro_Digestiv: (OTCBB: ACCP) FDA Approved MuGard Targets $1 Billion Market: Access Pharma CEO Jeffrey Davi... http://bit.ly/94TNJ
Accesspharma: RT @ProActiveNR: Part II - Q&A with Jeff Davis of Access Pharma (OTCBB: ACCP) http://tinyurl.com/2duc8h4
Accesspharma: RT @wkpetersbiz: Why MuGard will be successful. http://www.themarketfinancial.com/why-mugard-will-be-successful#News and Articles on Proactiveinvestors.com
- Access Pharma and iMedicor start marketing program for MuGard
- Access Pharma signs up BioScrip to distribute MuGard in US
- Access Pharma lands pre-licensing deal to develop oral formulation of injectable drugs
- Access Pharmaceuticals to Bring MuGard to Market in US in Q3
- Access Pharma CEO Davis to meet investors in New York ahead of MuGard launch
Categories
- Calendar and Coverage (36)
- Clinical data (23)
- Corporate (7)
- Product programs (71)
- Cobalamin (10)
- MuGard (33)
- ProLindac (11)
- Thiarabine (4)
- Strategic partnerships (36)
- Asia (6)
- Europe (7)
- North America (8)
Archives
Resources
Corporate Presentation
Corporate Fact Sheet
Scientific Publications
ProLindac™ Fact Sheet
MuGard™ Fact Sheet
Cobalamin™ Fact Sheet
Thiarabine Fact Sheet
Analyst Report - August 18, 2010
Analyst Report - July 27, 2010
Analyst Report - May 18, 2010
Analyst Report - Dec. 16, 2009
Analyst Report - Jul. 30, 2009
Analyst Report - Jul. 6, 2009
Analyst Report - Apr. 23, 2009Tags
ACCP Accupac acquisitions acute lymphocytic leukemia acute myeoid leukemia analyst report ASK B12 bioRASI BioScrip breast cancer Clinical data Cobalamin conferences DACH platinum drug diabetes drug delivery financing imedicor intellectual property interviews JCOM MacroChem MASCC media coverage MuGard news oral insulin oral mucositis outsidein research ovarian cancer Pexiganan pipeline product opportunities ProLindac rheumatoid arthritis RNAi Rodman & Renshaw LLC Somanta SpePharm Strategic partnerships targeted cancer therapy Thiarabine vmci zacksImages















